Tirzepatide: Dual GIP/GLP-1 Agonist Research, Mechanism & Clinical Trials

For informational and research purposes only. This article does not constitute medical advice.

What Is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly that functions as a dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is the first approved molecule in the “twincretin” class — a term coined to describe compounds that simultaneously target both major incretin pathways.

The peptide is based on the native GIP sequence with modifications that confer GLP-1R agonist activity, DPP-IV resistance, and albumin binding for once-weekly dosing. Key structural features include a C20 fatty diacid moiety enabling albumin binding (half-life approximately 5 days), and an Aib (alpha-aminoisobutyric acid) modification at position 2 for DPP-IV resistance.

Tirzepatide is approved under two brand names:

• Mounjaro — For type 2 diabetes (5 mg, 10 mg, 15 mg weekly subcutaneous injection)
• Zepbound — For chronic weight management (5 mg, 10 mg, 15 mg weekly subcutaneous injection)

What has made tirzepatide a landmark molecule is its clinical efficacy: the SURMOUNT-1 trial demonstrated 22.5% mean weight loss at the highest dose — substantially exceeding the 15–17% seen with semaglutide 2.4 mg in STEP trials. This established that dual incretin agonism could produce greater metabolic effects than GLP-1 receptor agonism alone.

The GIP System: The “Other” Incretin

While GLP-1 has dominated the incretin research field for two decades, GIP (glucose-dependent insulinotropic polypeptide) is actually the more abundant incretin hormone, accounting for approximately 60–70% of the incretin effect in healthy individuals. GIP is secreted by K-cells in the upper small intestine in response to nutrient intake.

GIP Biology

• Insulin secretion — Like GLP-1, GIP stimulates glucose-dependent insulin secretion from pancreatic beta cells through cAMP-mediated signaling. GIP accounts for the majority of the incretin effect in healthy physiology.
• Adipose tissue effects — GIP receptors (GIPR) are expressed on adipocytes, where GIP signaling influences lipid metabolism, adipogenesis, and fat storage. This adipose activity is a key differentiator from GLP-1, which has minimal direct adipose tissue effects.
• Bone metabolism — GIP has documented effects on bone formation, with GIPR expressed on osteoblasts. GIP signaling promotes osteoblast activity and bone mineralization.
• Central nervous system — GIPR is expressed in the brain, including hypothalamic regions involved in energy homeostasis, and in the area postrema.

The GIP Paradox in Obesity Research

GIP’s role in obesity has been paradoxical. GIP promotes fat storage in adipose tissue, leading some researchers to hypothesize that blocking (rather than activating) GIPR would be beneficial for weight loss. Indeed, GIPR antagonist antibodies have shown weight loss in preclinical models. Yet tirzepatide — a GIPR agonist — produces the most potent weight loss of any incretin-based therapy.

This paradox remains incompletely resolved but may involve several mechanisms:

• GIPR agonism at supraphysiological levels may cause receptor desensitization or internalization, producing a functional antagonism effect
• Central GIPR activation may reduce appetite through mechanisms distinct from peripheral fat storage effects
• The combination of GIPR and GLP-1R agonism may produce emergent properties not seen with either alone
• GIP may have different effects in lean versus obese physiology

How Tirzepatide Works: Dual Mechanism

Tirzepatide’s dual agonism produces a pharmacological profile that differs from pure GLP-1 agonists in several important ways:

• Biased GIPR agonism — Tirzepatide activates GIPR with approximately 5-fold higher potency than native GIP, but with a “biased” signaling profile that may preferentially activate certain intracellular pathways (cAMP) over others (beta-arrestin recruitment). This biased agonism may explain why GIPR activation by tirzepatide produces different metabolic effects than native GIP.
• GLP-1R agonism — Tirzepatide activates GLP-1R with approximately equal potency to native GLP-1, producing the well-characterized appetite suppression, glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay.
• Enhanced insulin sensitivity — Clinical data suggests tirzepatide improves insulin sensitivity to a greater degree than GLP-1 agonists alone, potentially through GIP-mediated effects on adipose tissue and hepatic metabolism. The SURPASS-3 MRI substudy documented reductions in liver fat content and visceral adipose tissue that exceeded expectations based on weight loss alone.
• Fat distribution effects — Tirzepatide has demonstrated preferential reduction of visceral (abdominal) fat compared to subcutaneous fat in imaging substudies. Visceral adiposity is more strongly associated with cardiometabolic risk than subcutaneous fat, making this preferential visceral fat loss clinically significant.
• Preserved lean mass — Some analyses suggest tirzepatide may preserve lean body mass to a slightly greater degree than GLP-1 agonists during weight loss, though this finding requires confirmation in larger, dedicated studies.

Clinical Trial Data

SURPASS Program (Type 2 Diabetes)

The SURPASS trials evaluated tirzepatide in type 2 diabetes:

• SURPASS-1 — Monotherapy: HbA1c reduction of 2.07% with tirzepatide 15 mg, with 52% of patients achieving HbA1c <5.7% (normal range).
• SURPASS-2 — Head-to-head vs. semaglutide 1 mg: Tirzepatide 15 mg produced significantly greater HbA1c reduction (-2.46% vs. -1.86%) and weight loss (-12.4 kg vs. -6.2 kg) than semaglutide.
• SURPASS-3 — Vs. insulin degludec: Tirzepatide produced superior glucose control while reducing weight by 11.7 kg (vs. insulin, which increased weight by 2.3 kg).
• SURPASS-4 — Cardiovascular safety: Met non-inferiority for MACE compared to insulin glargine, with numerically lower event rates.

SURMOUNT Program (Weight Management)

• SURMOUNT-1 — 2,539 non-diabetic adults. Mean weight loss: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) at 72 weeks. More than half of 15 mg participants lost ≥20% body weight.
• SURMOUNT-2 — 938 adults with type 2 diabetes. Mean weight loss: 12.8% (10 mg), 14.7% (15 mg) with concurrent HbA1c reductions of 2.1%.
• SURMOUNT-3 — Tirzepatide following intensive lifestyle intervention. Mean weight loss of 26.6% at 84 weeks (including the initial lifestyle phase), the largest mean weight reduction reported in any pharmaceutical obesity trial.
• SURMOUNT-4 — Withdrawal study confirming weight regain upon discontinuation, consistent with semaglutide findings.

Head-to-Head: Tirzepatide vs. Semaglutide

The SURPASS-2 trial provided the first direct comparison, showing tirzepatide’s superiority for both glucose control and weight loss in type 2 diabetes. However, SURPASS-2 used semaglutide 1 mg (the diabetes dose), not the 2.4 mg weight management dose. A dedicated head-to-head weight management comparison has not been published, though indirect comparisons consistently favor tirzepatide.

The Multi-Agonist Research Frontier

Tirzepatide’s success has catalyzed the development of additional multi-agonist incretin peptides:

Compound	Targets	Developer	Stage	Approx. Weight Loss
Tirzepatide	GIP + GLP-1	Eli Lilly	Approved	20–22%
Retatrutide	GIP + GLP-1 + Glucagon	Eli Lilly	Phase 3	24% (Phase 2)
Survodutide	GLP-1 + Glucagon	Boehringer Ingelheim	Phase 3	18–19% (Phase 2)
Mazdutide	GLP-1 + Glucagon	Innovent	Phase 3 (China)	15–17% (Phase 2)
CagriSema	Amylin (Cagrilintide) + GLP-1	Novo Nordisk	Phase 3	22–24% (Phase 2)
Pemvidutide	GLP-1 + Glucagon	Altimmune	Phase 2	15% (Phase 2)

The progression from single-agonist (semaglutide) to dual-agonist (tirzepatide) to triple-agonist (retatrutide) represents a clear trajectory in the field, with each additional receptor target producing incremental gains in weight loss efficacy. Retatrutide’s addition of glucagon receptor agonism — which enhances energy expenditure and hepatic fat oxidation — has produced the highest reported weight loss in clinical trials to date.

Side Effects and Safety Profile

Tirzepatide’s safety profile is broadly similar to GLP-1 agonists, with some notable differences:

• Gastrointestinal effects — Nausea, diarrhea, vomiting, and constipation are the most common adverse effects. Rates are comparable to or slightly lower than semaglutide at equipotent weight-reducing doses, possibly due to the GIP component moderating GLP-1-mediated nausea.
• Gallbladder events — Consistent with all rapid-weight-loss interventions, cholelithiasis rates are elevated.
• Thyroid C-cell tumors — Same class warning as GLP-1 agonists, based on rodent data not replicated in humans.
• Cardiovascular outcomes — SURPASS-4 met non-inferiority for cardiovascular safety. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) is ongoing.
• Injection site reactions — Generally mild and transient.

Summary

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that has established new benchmarks for both glycemic control and weight reduction. Its dual-agonist mechanism produces metabolic effects that exceed what GLP-1 agonism alone can achieve, including greater weight loss (20–22% in SURMOUNT trials), superior insulin sensitivity, preferential visceral fat reduction, and potentially better lean mass preservation. The success of this dual-agonist approach has validated the multi-agonist concept and catalyzed a wave of triple-agonist and combination peptide development. As the field advances toward triple agonists like retatrutide and amylin combinations like CagriSema, tirzepatide represents the inflection point at which incretin pharmacology moved beyond single-target therapy into the multi-receptor era.

For research peptides in the incretin and metabolic space, browse our catalog: Retatrutide, Cagrilintide, Survodutide, and Mazdutide.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Thomas et al.	2021	Review	Tirzepatide in SURPASS clinical trials for type 2 diabetes	PMC7843845
Willard et al.	2020	In Vitro	Tirzepatide as imbalanced and biased dual GIP/GLP-1 agonist	PMID 32730231
Wilson et al.	2020	Clinical Trial	Tirzepatide improves beta-cell function and insulin sensitivity	PMID 33236115
Karagiannis et al.	2022	Systematic Review	Management of type 2 diabetes with dual GIP/GLP-1 agonist tirzepatide	PMID 35579691
Dutta et al.	2023	Meta-Analysis	Efficacy and safety of tirzepatide in type 2 diabetes management	PMC10614386
Mishra et al.	2022	Review	Tirzepatide – dual GIP/GLP-1 agonist with metabolic activity	PMID 35593668
Syed	2022	Review	Tirzepatide for type 2 diabetes with unmatched glycaemic control	PMID 36050763
Sharma et al.	2025	Review	Tirzepatide therapeutic spectrum: metabolic, neurological, cardiovascular	PMC12507501

Written by NorthPeptide Research Team

This article is for informational and research purposes only. It does not constitute medical advice. NorthPeptide does not sell tirzepatide. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.